Overexpression of p53 in duodenal tumours in patients with familial adenomatous polyposis

British Journal of Surgery

Volumn 83, Issue 2, 1996, Pages 225-228

  Kashiwagi, H ^a,c   Spigelman, A D ^a,b   Talbot, I C ^a   Phillips, R K S ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TUMOR MARKER;

ARTICLE; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUODENUM TUMOR; FAMILIAL POLYPOSIS; GASTROINTESTINAL POLYPOSIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADENOMATOUS POLYPOSIS COLI; DUODENAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030071166     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800830223     Document Type: Article

References (32)

1. Nugent KP, Spigelman AD, Phillips RKS. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum 1993; 36: 1059-62.
2. Jagelman DG, DeCosse JJ, Bussey HJR. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet 1988; i: 1149-51.
3. Iwama T, Mishima Y, Utsunomiya J. The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg 1993; 217: 101-8.
4. Spigelman AD, Talbot IC, Penne C et al. Evidence for adenoma-carcinoma sequence in the duodenum of patients with familial adenomatous polyposis. The Leeds Castle Polyposis Group (Upper Gastrointestinal Committee). J Clin Pathol 1994; 47: 709-10.
5. Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RKS. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989; ii: 783-5.
6. Bennett WP, Hollstein MC, He A et al. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene 1991; 6: 1779-84.
7. Shiao Y, Rugge M, Correa P, Lehmann HP, Scheer WD. p53 alteration in gastric precancerous lesions. Am J Pathol 1994; 144: 511-17.
8. Kikuchi-Yanashita R, Konishi M, Ito S et al. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 1992; 52: 3965-71.
9. Barton CM, Staddon SL, Hughes CM et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64: 1076-82.
10. Hill MJ. Microbes and Human Carcinogenesis. London: Edward Arnold, 1986: 56-107.
11. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9.
12. Rodrigues NR, Rowan A, Smith MEF et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 1990; 87: 7555-9.
13. Ogden GR, Kiddie RA, Lunny DP, Lane DP. Assessment of p53 protein expression in normal, benign, and malignant oral mucosa. J Pathol 1992; 166: 389-94.
14. Flejou JF, Potet F, Muzeau F, Le Pelletier F, Fekete F, Henin D. Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J Clin Pathol 1993; 46: 330-3.
15. Joypaul BV, Newman EL, Hopwood D et al. Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: an immunohistochemical study. J Pathol 1993; 170: 279-83.
16. van den Berg FM, Tigges AJ, Schipper MEI, den Hartog-Jager FCA, Kroes WGM, Walboomers JMM. Expression of the nuclear oncogene p53 in colon tumours. J Pathol 1989; 157: 193-9.
17. Kaklamanis L, Gatter KC, Mortensen N et al. p53 expression in colorectal adenomas. Am J Pathol 1993; 142: 87-93.
18. Yukawa M, Fujimori T, Maeda S, Tabuchi M, Nagasako K. Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours. Gut 1994; 35: 1258-61.
19. Maddox PH, Jenkins D. 3-Aminopropyltriethoxysilane (APES): a new advance in section adhesion. J Clin Pathol 1987; 40: 1256-7.
20. Cattoretti G, Pileri S, Parravicini C et al. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 1993; 171: 83-98.
21. Taylor CR, Shi SR, Chaiwun B, Young L, Imam SA, Cote RJ. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol 1994; 25: 263-70.
22. Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. Adenocarcinoma arising in Barrett's oesophagus; evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut 1994; 35: 764-8.
23. Scarpa A, Capelli P, Zamoni G et al. Neoplasia of the ampulla of Vater: Ki-ras and p53 mutations. Am J Pathol 1993; 142: 1163-72.
24. 32P-postlabelling, in the foregut of patients with familial adenomatous polyposis and in unaffected controls. Carcinogenesis 1991; 12: 1727-32.
25. Makino H, Ishizaki Y, Tsujimoto A et al. Rat p53 gene mutations in primary Zymbal gland tumors induced by 2-amino-methylimidazo[4,5-f]quinoline, a food mutagen. Proc Natl Acad Sci U S A 1992; 89: 4850-4.
26. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-3.
27. Kastan MB, Zhan Q, el-Deiry WS et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-97.
28. Hall PA, McKee PH, Menage HD, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993; 8: 203-7.
29. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992; 89: 7491-5.
30. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993; 8: 307-18.
31. Barnes DM, Hanby AM, Gillett CE et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992; 340: 259-63.
32. Lane DP. The regulation of p53 function: Steiner Award Lecture. Int J Cancer 1994; 57: 623-7.